July 11, 2016 11:29 AM EDTUpdated July 12, 06:08 AM
Bioregnum
Pharma
Opinion

Knock it off: Biosim­i­lars are not a 'knock­of­f' drug

I like nice Nikes. Some can get pricey. Would I’d nev­er wear a knock­off? No.

 

Let’s start at square one by ask­ing …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Drug­mak­ers see a sub­stan­tial, but man­age­able, hit to busi­ness from tar­iffs. But the worst may lie ahead

Bris­tol My­ers CEO sig­nals deal­mak­ing will be a top pri­or­i­ty in 2025

Roche CEO warns that tar­iffs could im­pact deal­mak­ing

Roche takes steps to pro­tect it­self from tar­iffs, while Sanofi hangs back

Sanofi's Al­tuvi­i­io clos­ing in on block­buster sta­tus, Dupix­ent sales surge

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times